AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02799030
Drug: BF-200 ALA 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
Trial: NCT02799030
Drug: BF-200 ALA 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
Trial: NCT02799030
Drug: BF-200 ALA 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
Trial: NCT02926430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo as formulation buffer.
Trial: NCT00044668
Drug: AC2993
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.
Trial: NCT00349726
Drug: Inositol lower volume
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
Trial: NCT00349726
Drug: Inositol higher volume
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120 mg/kg (2.4ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
Trial: NCT04273581
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg/d，qn，for 14 days.
Trial: NCT03053219
Drug: AC0010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
Trial: NCT01593033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
Trial: NCT01574326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
Trial: NCT02379806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01128257
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed by physician
Trial: NCT04447261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02238626
Drug: Placebo (for MN-166)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02238626
Drug: MN-166
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04613674
Drug: placebo+chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo+chemotherapy
Trial: NCT02939898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy to recFSH during ovarian stimulation
Trial: NCT03001219
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will continue their pre-trial methotrexate therapy at a stable dose.
Trial: NCT03001219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intravenous infusion of placebo.
Trial: NCT03001219
Drug: RO7123520
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intravenous infusion of RO7123520.
Trial: NCT01403064
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT02528123
Drug: Proxymetacaine 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure
Trial: NCT02528123
Drug: Oxybuprocaine 0.4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure
Trial: NCT01195103
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients \<60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
Trial: NCT00862745
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
Trial: NCT00548925
Drug: ABT-894
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg BID tablets, 8 weeks of treatment
Trial: NCT00548925
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID tablets, 8 weeks of treatment
Trial: NCT01939496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
Trial: NCT03178526
Drug: Lovastatin gel
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin gel1.2% topical gel was put into teh periodontal pocket using an insulin syringe
Trial: NCT03178526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo gel
Trial: NCT03052322
Drug: MSB11022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received MSB11022 (modified buffer and stabilizer) subcutaneously at dose of 40 milligram (mg) every other week from Day 1 up to Week 48.
Trial: NCT03052322
Drug: EU-Humira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.
Trial: NCT02398357
Drug: Nadroparin Calcium and Warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
Trial: NCT00345735
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04326348
Drug: TQ05105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ05105 is a JAK2 inhibitor.
Trial: NCT00589563
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60mg/kg on days -5 and -4 from stem cell transplant
Trial: NCT00589563
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
Trial: NCT03000218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 to 56: Placebo bid
Trial: NCT01610544
Drug: 3'-deoxy-3'-18F fluorothymidine (FLT)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003093
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003093
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00469157
Drug: Optive
RxNorm normalized name: optive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
Trial: NCT00774696
Drug: clarithromycin 500mg tablets
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00874003
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, 1 daily
Trial: NCT01988506
Drug: Interleukin 2
RxNorm normalized name: Recombinant interleukin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months
Trial: NCT04642937
Drug: Treatment with hP1A8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with hP1A8
Trial: NCT02717858
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected s.c./subcutaneously (under the skin) once daily.
Trial: NCT00563251
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00563251
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00732615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for subcutaneous injection
Trial: NCT00732615
Drug: NPSP558
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
Trial: NCT00204607
Drug: GM-CSF s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00413686
Drug: AZD7762
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT00063635
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT02059018
Drug: COX-inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
Trial: NCT03577704
Drug: HLX07+mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.~HLX07, IV, weekly.
Trial: NCT01103622
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet bd, step-wise increased dosage
Trial: NCT01103622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet bd, step-wise increased dosage
Trial: NCT02758522
Drug: Once-daily Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive NPH insulin in a once-daily regimen. The starting dose is calculate according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the once-daily regimen will be administered subcutaneously before breakfast. Regular insulin subcutaneously wil be given in three equally divided doses before each meal.
Trial: NCT02758522
Drug: Twice-daily Insulin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive NPH insulin in twice-daily regimen. The starting dose is calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will de fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the twice-daily regimen will be administered subcutaneously before breakfast and before dinner. Regular insulin will be given in three equally divided doses before each meal.
Trial: NCT02758522
Drug: Triple-daily Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive NPH insulin in a triple-daily regimen. The starting dose was calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the triple daily regimen will be administered subcutaneously before each meal. Regular insulin will be given in three equally divided doses before each meal.
Trial: NCT00306150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is used according to the description of Arm 1
Trial: NCT00988065
Drug: Placebo run-in dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
Trial: NCT00988065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
Trial: NCT03979820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT00706381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV and/or oral placebo
Trial: NCT01555008
Drug: LX4211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive LX4211 once daily for 7 days
Trial: NCT01555008
Drug: LX4211 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive LX4211 placebo once daily for 7 days
Trial: NCT01483469
Drug: RO4917523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally daily, 14 days
Trial: NCT01483469
Drug: RO5011232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[11C\]-RO5011232 intravenously
Trial: NCT04262661
Drug: NNC0472-0147
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort.
Trial: NCT04262661
Drug: Placebo (NNC0472-0147)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: A single dose of placebo, dose increased in each cohort.
Trial: NCT00453817
Drug: ferucarbotran (iron-based MRI contrast agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: islets will be incubated with ferucarbotran prior to transplantation, for imaging after transplantation
Trial: NCT02487381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04435106
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants received Standard of Care
Trial: NCT00110162
Drug: antiandrogen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02547402
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It is statin medicine used to lower cholesterol and triglycerides in the blood.
Trial: NCT02547402
Drug: Vytorin® (combination of simvastatin and ezetimibe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It lowers bad cholesterol in the blood, and raises good cholesterol
Trial: NCT00513682
Drug: Ultrase® MT20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
Trial: NCT02317549
Drug: LB1148
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02317549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02539277
Drug: Jinyebaidu granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
Trial: NCT02539277
Drug: Fufangshuanghua granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
Trial: NCT02539277
Drug: Jinyebaidu granule placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is Jinyebaidu granule placebo.
Trial: NCT02539277
Drug: Fufangshuanghua granule placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is Fufangshuanghua granule placebo.
Trial: NCT00293644
Drug: Diclectin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
Trial: NCT01598012
Drug: Ayurved Siriraj Prasaplai with or without mefenamic acid
RxNorm normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)
Trial: NCT01598012
Drug: Placebo with or without mefenamic acid
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
Trial: NCT00722033
Drug: 3 protocols of Indomethacin administration
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
Trial: NCT00530764
Drug: Sativex Medium Dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
Trial: NCT00712205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily 1mcg Placebo for 28days followed by crossover treatment
Trial: NCT04495283
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
Trial: NCT01301586
Drug: Doxycycline and S-equol
RxNorm normalized name: S-equol
DrugBank: Equol (DB11674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline and s-equol twice a day
Trial: NCT01301586
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ORAL DOXYCYCLINE TWICE A DAY
Trial: NCT00796263
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily~Dolutegravir(DTG) 50 mg orally once daily
Trial: NCT01428050
Drug: 3% NaCl Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution
Trial: NCT02470390
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
Trial: NCT00721552
Drug: Prednisolone 30 mg
RxNorm normalized name: prednisolone 30 MG
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 days administration of 30 mg daily
Trial: NCT00721552
Drug: Prednisolone-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 days administration once daily
Trial: NCT00759811
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks.
Trial: NCT00759811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks.
Trial: NCT04132583
Drug: Deflox®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions.
Trial: NCT04132583
Drug: Cataflam DD®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions.
Trial: NCT03858166
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.
Trial: NCT00345059
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00220402
Drug: SPM 907
FDA approved: no
EMA approved: no
PMDA approved: no